Brief: Genocea To Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine Gen-009 In Combination With Checkpoint Inhibitors
30/07/2020 13:44
July 30 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA TO PRESENT POSITIVE PRELIMINARY CLINICAL DATA
EVALUATING
NEOANTIGEN VACCINE GEN-009 IN COMBINATION WITH CHECKPOINT
INHIBITORS
* GENOCEA BIOSCIENCES INC - THREE OF FIVE PATIENTS ACHIEVED
SEPARATE RECIST RESPONSES AFTER GEN-009 ADMINISTRATION
* GENOCEA BIOSCIENCES INC - GEN-009 ELICITED
ANTIGEN-SPECIFIC
CD4(+) AND CD8(+) T CELL RESPONSES IN 100% OF TREATED PATIENTS
Source text for Eikon: ID:nGNX7h0bhD
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc